Cargando…

Understanding of BRCA VUS genetic results by breast cancer specialists

BACKGROUND: Mainstreaming genetic medicine, increased media coverage and clinical trials for BRCA mutation carriers are leading oncologists into more patient discussions about BRCA genetic testing. BRCA variants of uncertain significance (VUS) occur in 10–20 % of tests. VUS detection introduces addi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eccles, B. K., Copson, E., Maishman, T., Abraham, J. E., Eccles, D. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660681/ https://www.ncbi.nlm.nih.gov/pubmed/26608569 http://dx.doi.org/10.1186/s12885-015-1934-1

Ejemplares similares

Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
por: McKenzie, Hayley S., et al.
Publicado: (2020)

Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study
por: Copson, E, et al.
Publicado: (2014)

An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis
por: Maishman, T, et al.
Publicado: (2015)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study
por: Maishman, Tom, et al.
Publicado: (2017)

Missense Variants of Uncertain Significance (VUS) Altering the Phosphorylation Patterns of BRCA1 and BRCA2
por: Tram, Eric, et al.
Publicado: (2013)

A review of the online prognositc model predict using the POSH cohort (women aged ≤40 years at breast cancer diagnosis)
por: Maishman, Tom, et al.
Publicado: (2015)

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
por: Copson, Ellen R, et al.
Publicado: (2018)

Parlez-vous VUS?
por: Cooper, Gregory M.
Publicado: (2015)

Classification of VUS and unclassified variants in BRCA1 BRCT repeats by molecular dynamics simulation
por: Sinha, Siddharth, et al.
Publicado: (2020)

BRCA1 VUS: A functional analysis to differentiate pathogenic from benign variants identified in clinical diagnostic panels for breast cancer
por: Lourenço, Rita Adubeiro, et al.
Publicado: (2023)

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers
por: Copson, Ellen R, et al.
Publicado: (2006)

Identification of personal risk of breast cancer: genetics
por: Eccles, Diana M
Publicado: (2008)

BRCA1 polymorphisms.
por: Campbell, I. G., et al.
Publicado: (1997)

$|V_us|$ and $m_s$ from hadronic tau decays
por: Gamiz, Elvira, et al.
Publicado: (2006)

Exome Sequencing in an ADSHE Family: VUS Identification and Limits
por: Villa, Chiara, et al.
Publicado: (2022)

Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules
por: Jimenez-Sainz, Judit, et al.
Publicado: (2021)

Les rayons cosmiques vus par les grands détecteurs
Publicado: (1999)

Theoretical progress on the V_us determination from tau decays
por: Gamiz, Elvira, et al.
Publicado: (2007)

How Functional Genomics Can Keep Pace With VUS Identification
por: Anderson, Corey L., et al.
Publicado: (2022)

BRCA1 mutations in southern England.
por: Eccles, D. M., et al.
Publicado: (1998)

Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort
por: Watson, M, et al.
Publicado: (2004)

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
por: Hu, Chunling, et al.
Publicado: (2022)

A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations
por: An, Q, et al.
Publicado: (2010)

VUS-type alteration in POLD1 and microsatellite instability in a metastatic luminal B breast cancer patient
por: da Silva, Catarina Marchon, et al.
Publicado: (2020)

Interpreting ciliopathy-associated missense variants of uncertain significance (VUS) in Caenorhabditis elegans
por: Lange, Karen I, et al.
Publicado: (2021)

How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
por: Kwong, Ava, et al.
Publicado: (2022)

Understanding the symptoms of the common cold and influenza
por: Eccles, Ron
Publicado: (2005)

Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing
por: Fallowfield, Lesley, et al.
Publicado: (2022)

DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes
por: Richardson, Marcy E., et al.
Publicado: (2018)

Correction: DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes
por: Richardson, Marcy E., et al.
Publicado: (2018)

Experimental prospects for Vud , Vus , Vcd , Vcs and (semi-)leptonic D decays at LHCb
por: Davis, Adam
Publicado: (2018)

High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer
por: Eccles, D, et al.
Publicado: (2006)

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
por: Robertson, L, et al.
Publicado: (2012)

Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up
por: Foster, C, et al.
Publicado: (2007)

Conversion 1997 du timing du PS-Booster aspects vus par l’utilisateur actuel
por: Schnell, J D
Publicado: (1996)

Melanoma Genetics/Genomics
por: Eccles, Michael R.
Publicado: (2013)

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
por: Girardi, Fabio, et al.
Publicado: (2018)

Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices
por: Toland, Amanda Ewart, et al.
Publicado: (2018)

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
por: Maia, Ana-Teresa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vo201g5grtl3d4an8rvpcslbr7